Notable Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Mateo healthcare AI platform automating patient intake, insurance verification, care gap identification, and post-visit follow-up for health systems via EHR-connected AI agents.
About
Notable Health is a San Mateo-based healthcare AI company that provides health systems with an automation platform that handles repetitive clinical and administrative tasks — patient intake, pre-visit questionnaires, insurance verification, care gap identification, and post-visit follow-up — using AI agents deployed on health system infrastructure. Notable's platform connects to EHR systems to understand each patient's care context and proactively sends personalized communications and automated workflows at the right moments in the patient journey. By automating tasks that currently consume significant time from nurses, medical assistants, and front desk staff, Notable enables health systems to manage the same patient volume with fewer administrative staff or improve throughput without hiring. The company has documented millions of automated care actions with customers including Intermountain Health and Stanford Medicine. Founded in 2017, Notable raised over $100M from investors including F-Prime Capital, BOND, and Oak HC/FT, and competes with Olive AI (now closed) and Regard in the healthcare automation market.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.